US FDA Dismisses PostProgression Endpoint In Cyramza Lung Cancer Study
US FDA Dismisses Post-Progression Endpoint In Cyramza Lung Cancer Study
Lilly included progression-free survival 2 as an exploratory endpoint in RELAY on the advice of the European Medicines Agency...
Original Article: US FDA Dismisses Post-Progression Endpoint In Cyramza Lung Cancer Study
More From BioPortfolio on "US FDA Dismisses Post-Progression Endpoint In Cyramza Lung Cancer Study"